Perceptive Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$178M Sell
4,373,974
-50,000
-1% -$1.72M 2.67% 11
2026
Q1
$139M Sell
4,423,974
-34,000
-0.8% -$980K 2.72% 9
2025
Q4
$111M Buy
4,457,974
+662,080
+17% +$13.3M 1.97% 13
2025
Q3
$61.6M Sell
3,795,894
-844,055
-18% -$12M 1.78% 19
2025
Q2
$60.8M Sell
4,639,949
-1,907,379
-29% -$27.5M 2.26% 9
2025
Q1
$144M Buy
6,547,328
+3,861,791
+144% +$101M 5.09% 4
2024
Q4
$71.7M Buy
2,685,537
+355,243
+15% +$11.3M 1.98% 13
2024
Q3
$62.2M Buy
2,330,294
+473,877
+26% +$9.43M 1.32% 26
2024
Q2
$33.4M Sell
1,856,417
-463,229
-20% -$8.08M 0.81% 37
2024
Q1
$42.3M Buy
2,319,646
+1,764,091
+318% +$28M 0.74% 45
2023
Q4
$6.08M Buy
+555,555
New +$3.9M 0.14% 72

Other funds holding EWTX

Perceptive Advisors's EWTX Position: Q2 2026 in Review

Perceptive Advisors reduced its Edgewise Therapeutics (EWTX) stake by 1.1% in Q2 2026, selling an estimated $1.72M and leaving 4,373,974 shares worth $178M. The position accounts for 2.67% of the portfolio, ranked #11.

Perceptive Advisors first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Perceptive Advisors held 4,373,974 shares of Edgewise Therapeutics worth $178M as of Q2 2026.
  • Perceptive Advisors sold 50,000 Edgewise Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Edgewise Therapeutics made up 2.67% of Perceptive Advisors's portfolio in Q2 2026, its #11 holding.
  • Perceptive Advisors first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.